The Sultanate is set to host a highly anticipated Digital Innovation & Transformation Summit on the 28th – 29th of Feb 2024. This is a business-focused event driven by thought leadership, which delves deeply into the latest challenges and technology
India and the United States have agreed to expand collaboration in areas such as medicines, semiconductors, vital minerals, and new technology. According to the trade ministry, the two nations also addressed cooperation prospects in green and...
KromaTiD and SeQure Dx announced a collaboration to commercialize a complete and integrated study of off-target gene editing in support of cell and gene therapy research, IND applications, and medicinal product development. The combination of...
The United States Food and Drug Administration (USFDA) has granted final clearance to Zydus Lifesciences for Ivabradine tablets, 5 mg and 7.5 mg (USRLD: Corlanor Tablets, 5 mg and 7.5 mg). Ivabradine is indicated to reduce the risk of...
Ascendis Pharma A/S announced an exclusive licensing agreement with Teijin Limited for the further development and marketing of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare illness in Japan. “We are pleased to partner with...
Boehringer Ingelheim and IBM established a collaboration in which Boehringer would leverage IBM's foundation model technology to uncover unique candidate antibodies for the development of effective medicines. “We are very excited to collaborate...
A notable pharmaceutical company in India faced significant challenges in overseeing its complex IT infrastructure. Obsolete legacy systems, inconsistent data sources, and the need to comply with strict regulatory requirements hampered innovation.
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced that Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, has been approved by the US Food and Drug...
India's HempStreet and the first Ayurvedic cannabis research retail company have raised $1 million in a pre-A round. The round was led by their current investor,
Swedish pharmaceutical company Orexo AB (publ.) announces that the US Food and Drug Administration (FDA) have approved